phenylacetylglutamine has been researched along with Coronary Artery Disease in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brunkwall, L; Fernandez, C; Melander, O; Nilsson, PM; Orho-Melander, M; Ottosson, F; Smith, E | 1 |
| Liu, H; Liu, S; Liu, Y; Qu, H; Song, X; Zhao, Z | 1 |
1 review(s) available for phenylacetylglutamine and Coronary Artery Disease
| Article | Year |
|---|---|
The gut microbiota-related metabolite phenylacetylglutamine associates with increased risk of incident coronary artery disease.
Topics: Adult; Aged; Chromatography, Liquid; Cohort Studies; Coronary Artery Disease; Female; Gastrointestinal Microbiome; Glutamine; Humans; Male; Mass Spectrometry; Metabolomics; Middle Aged; Prospective Studies; RNA, Ribosomal, 16S | 2020 |
1 other study(ies) available for phenylacetylglutamine and Coronary Artery Disease
| Article | Year |
|---|---|
Phenylacetylglutamine is associated with the degree of coronary atherosclerotic severity assessed by coronary computed tomographic angiography in patients with suspected coronary artery disease.
Topics: Computed Tomography Angiography; Coronary Angiography; Coronary Artery Disease; Coronary Stenosis; Glutamine; Humans; Plaque, Atherosclerotic; Predictive Value of Tests; Prospective Studies; Registries; Severity of Illness Index; Tomography, X-Ray Computed | 2021 |